NDAC/antiviral committee meeting
This article was originally published in The Tan Sheet
Executive Summary
Tentatively scheduled for Jan. 12-13. FDA has not announced the topics for the meeting. However, reconsideration of the Rx-to-OTC switch of Burroughs Wellcome's Zovirax (acyclovir) in the treatment of genital herpes is awaiting consideration by the joint committee. The committee postponed a decision on the switch in July to allow Burroughs Wellcome time to submit data that addressed issues raised at an FDA public hearing on May 19 ("The Tan Sheet" July 4, p. 1). Other tentative 1995 meeting dates for NDAC include March 27-28; July 13-14; Sept. 28-29 and Nov. 16-17